Cerebrolysin for vascular dementia

Area of Science:

• Neurology
• Clinical Trials
• Evidence-Based Medicine

Background:

• Vascular dementia is a leading cause of global dementia with limited evidence-based treatments.
• Cerebrolysin, a brain-derived preparation, is used intravenously for vascular dementia.
• This review updates a previous Cochrane Review, employing contemporary methods to assess evidence strength.

Purpose of the Study:

• To evaluate Cerebrolysin's effect on cognitive function, global function, and mortality in vascular dementia.
• To assess adverse effects, quality of life, and caregiver burden associated with Cerebrolysin treatment.

Main Methods:

• Systematic review and meta-analysis of randomized controlled trials (RCTs).
• Searched multiple databases including ALOIS, MEDLINE, Embase, and Chinese databases up to May 2019.
• Assessed evidence strength using the GRADE approach.

Main Results:

• Six RCTs with 597 participants were included; no new studies were identified since 2013.
• Cerebrolysin showed a beneficial effect on cognitive function (SMD 0.36, very low-quality evidence).
• Global function also improved with Cerebrolysin (RR 2.69, very low-quality evidence), with no increased adverse events.

Conclusions:

• Intravenous Cerebrolysin may improve cognition and global function in vascular dementia patients.
• The current evidence is limited by high risk of bias and heterogeneity, with potential benefits being clinically marginal.
• High-quality, adequately powered RCTs are essential to definitively establish Cerebrolysin's efficacy in vascular dementia.